Trinity Biotech (Nasdaq:TRIB) today announced its plans to add another continuous glucose monitor (CGM) system to the growing market.
Our sister site, Drug Delivery Business News, reports today that the company unveiled CGM+, a next-gen wearable biosensor, aims to take on the growing AI wearables market.
The Dublin, Ireland-based company said it has the system in the later stages of device development. The new AI-native CGM combines multi-sensor data with real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.
Unlike traditional CGMs focused solely on glucose monitoring, Trinity says CGM+ offers a variety of measurements. It combines an ultra-thin, minimally invasive electrochemical glucose sensor with the monitoring of heart activity, body temperature and physical activity, all within one sleek, user-friendly, modular wearable device.
Get the full story at our sister site, Drug Delivery Business News.
